Aquestive Therapeutics, Inc.

AQST · Nasdaq · United States

Share price · AQST

$3.78-0.54 (-12.50%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AQST's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Nov 2026+9.5%

    Nothing announced by AQST that day or the session before.

  2. 15 Oct 2026-11.9%
  3. 26 Aug 2026+6.1%

    Nothing announced by AQST that day or the session before.

  4. 10 Aug 2026+8.9%
  5. 29 Jun 2026-5.2%

    Nothing announced by AQST that day or the session before.

  6. 25 Jun 2026-10.5%

    Nothing announced by AQST that day or the session before.

  7. 15 May 2026-11.8%

    Nothing announced by AQST that day or the session before.

  8. 14 May 2026+14.5%
  9. 2 Feb 2026+39.0%
  10. 9 Jan 2026-37.0%

Share of unusual movement by asset

For each asset, the share of AQST's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Dibutepinephrine (Anaphylm) (Anaphylm)
events and moves
6shown from 8 days
Diazepam (Libervant) (Libervant)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—15%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—48%

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
GABA-A receptor (benzodiazepine site)Small molecule
EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome
Phase 3
GABA-A receptorSmall molecule
Epilepsy
Preclinical / Unstaged
Alpha- and beta-adrenergic receptors (agonist)Small molecule
Allergic Conditions
Anaphylaxis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

16 March 2027FDA action dateAnaphylmPDUFA goal date for the Anaphylm NDA resubmission
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
29 March 2027FDA action dateLibervant (diazepam) buccal filmPDUFA date for the Libervant Type 9 NDA (ages 6 to 11)
US, FDA · Aquestive Therapeutics, Inc. (US licensee Eton Pharmaceuticals from 2026-10-14) · Source ↗

Recent

15 October 2026Filing acceptedAnaphylmFDA accepts the Anaphylm NDA resubmission (Class 2)
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
September 2026Filing submittedAnaphylmAnaphylm NDA resubmitted after complete response letter
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
10 August 2026Topline resultAnaphylmTopline human factors and pharmacokinetic study results for Anaphylm
Aquestive Therapeutics, Inc. · Source ↗
31 January 2026FDA action dateAnaphylmAnaphylm NDA PDUFA target action date
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
30 January 2026Complete response letterAnaphylmFDA issues complete response letter for Anaphylm
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
16 June 2025Filing acceptedAnaphylmFDA accepts Anaphylm NDA
US, FDA · Aquestive Therapeutics, Inc. · Source ↗
March 2025Filing submittedAnaphylmOriginal Anaphylm NDA submitted to the FDA
US, FDA · Aquestive Therapeutics, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$7.6M$4.3M$90M$17M-$7.0M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$14M$4.0M$98M$23M-$9.4M operating cash flowreport ↗
2026-Q1$14M$4.2M$111M$8.1M-$15M operating cash flowreport ↗
2025-Q3$13M$4.5M$129M$15M-$13M operating cash flowreport ↗
2025-Q2$10M$4.1M$61M$14M-$7.9M operating cash flowreport ↗
2025-Q1$8.7M$5.4M$69M$23M-$23M operating cash flowreport ↗
2024-Q3$14M$5.3M$78M$12M-$12M operating cash flowreport ↗
2024-Q2$20M$4.2M$90M$2.8M-$7.0M operating cash flowreport ↗
2024-Q1$12M$5.9M$95M$13M-$10M operating cash flowreport ↗
2023-Q3$13M$3.2M$25M$2.0M-$2.4M operating cash flowreport ↗
2023-Q2$13M$3.5M$22M$5.8M-$7.9M operating cash flowreport ↗
2023-Q1$11M$3.5M$27M—$8.8M operating cash flowreport ↗
2022-Q3$11M$3.2M$19M$13M$2.8M operating cash flowreport ↗
2022-Q2$13M$5.2M$18M$16M-$6.6M operating cash flowreport ↗
2022-Q1$12M$4.8M$15M$13M-$14M operating cash flowreport ↗
2021-Q3$13M$4.7M$31M$15M-$9.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$45M$17M$121M$21M-$52M operating cash flowreport ↗

Aquestive reported full-year 2025 revenue of $44.55M, down 22.6% YoY, with R&D spend of $17.19M, down 15.2% YoY. Cash and equivalents stood at $121.17M, and the company reported a net loss of $83.78M, with a quarterly net burn of $83.78M.

The company reaffirmed guidance to resubmit the Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026 following a Complete Response Letter, with a Type A FDA meeting expected within 30 days, and plans regulatory submissions in Canada and the EU in 2026. FY2026 guidance includes total revenue of $46M to $50M, non-GAAP adjusted EBITDA loss of $35M to $30M, and year-end cash of $70M. AQST-108 Phase 1 dosing was completed with a data readout expected in Q2 2026, and the revenue-sharing agreement with RTW was extended to June 30, 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$58M$20M$72M$11M-$36M operating cash flowreport ↗
2023-FY$51M$13M$24M$2.0M-$6.4M operating cash flowreport ↗
2022-FY$48M$17M$27M$14M-$9.8M operating cash flowreport ↗
2021-FY$51M$17M$28M$18M-$33M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($99K), 17 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12Davis Matthew W. · Chief Development OfficerOpen-market sale7,197$3.55$26KForm 4
2026-11-10Davis Matthew W. · Chief Development OfficerTax withholding5,303$3.52$19KForm 4
2026-11-10Daly Richard J · directorOpen-market purchase1,200$3.53$4KForm 4
2026-11-10Daly Richard J · directorOpen-market purchase26,825$3.54$95KForm 4
2026-11-06Daly Richard J · directorAward / grant (derivative)57,000——Form 4
2026-10-21Cochran John · directorOther (see filing)62,229——Form 4
2026-10-15Barber Daniel · director, President and CEOOpen-market sale25,000$4.22$106KForm 4
2026-09-15Barber Daniel · director, President and CEOOpen-market sale25,000$4.82$120KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 178 reporting institutions held 71.8M shares ($293.1M, 57.1% of shares outstanding).

#InstitutionSharesValue
1Bratton Capital Management, L.P.9,810,958$40.7M
2BlackRock, Inc.7,509,071$31.2M
3RTW INVESTMENTS, LP7,426,471$30.8M
4VANGUARD CAPITAL MANAGEMENT LLC4,443,698$18.4M
5FEDERATED HERMES, INC.2,940,339$12.2M
6Balyasny Asset Management L.P.2,900,570$12.0M
7STATE STREET CORP2,546,191$10.6M
8SAMSARA BIOCAPITAL, LLC2,500,000$10.4M
9GEODE CAPITAL MANAGEMENT, LLC2,408,191$10.0M
10BANK OF AMERICA CORP /DE/2,405,050$10.0M
11Sio Capital Management, LLC1,922,887$8.0M
12MORGAN STANLEY1,591,792$6.6M
13Blue Owl Capital Holdings LP1,347,932$5.6M
14TWO SIGMA INVESTMENTS, LP1,139,404$4.7M
15COMMONWEALTH EQUITY SERVICES, LLC1,082,680$4.5M